The Cardiovascular diseases (CVDs) are the number 1 cause of death globally: more people die annually from CVDs than from any other cause. It accounts for more than 17 million deaths a year and that figure is rising. In Jordan, 36 per cent of deaths in Jordan are due to cardiovascular diseases, 34 per cent of which are among people under the age of 60.
Triumpharma has a network of Cardiovascular experts, who are highly-experienced in clinical research and drug development. They include representatives from all critical functional areas and overseas trial operations in order to anticipate and proactively address potential roadblocks.
Triumpharma experience in Cardiovascular diseases Clinical trials
We have over 10 years of experience in conducting cardiovascular trials, with particular emphasis on key cardiovascular/metabolic indications: heart failure, lipid disorders, diabetes, renal insufficiency and renal transplant, arrhythmia, and rare diseases.
Triumpharma has conducted several Cardiovascular clinical trials on both healthy subjects and patients to evaluate the pharmacokinetics, safety and tolerability of either single dose drug when administered alone and after multiple doses, to assess the potential effect of the drug in the steady state pharmacokinetics , and to assess the multiple dose pharmacokinetics and pharmacodynamics, as well as double blind controlled trials on atherosclerotic peripheral vascular disease.